immunology

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Rubius launches $200m IPO to fund red blood cell therapies

Rubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel cell therapies targeting cancer and autoimmune diseases.

News

NIH abandons convalescent plasma trial in mild COVID

Another trial of convalescent plasma in people with COVID-19 has missed the mark, this time in mild to moderate disease, further dashing hopes that the therapy could have an impact on the i

News

Data sets up ulcerative colitis expansion for BMS’ MS drug Z...

Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – and new data in ulcerative colitis suggests they could climb

News

Blood sample with respiratory coronavirus positive

IL-6 hypothesis looking shaky as Kevzara fails COVID-19 tria...

Hopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results from the first large-scale trial of Sanofi

News

There are three types of white blood cells. T lymphocytes, B lymphocytes and natural killer cells.

Kadmon preps filing for GVHD drug belumosudil after phase 3 ...

New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit the mark in a pivotal trial.

Views & Analysis

Innovating in inflammation and immunology

For World Inflammatory Bowel Disease day we spoke to Pfizer’s Matt Shaulis, president of international developed markets for inflammation and immunology, to hear how the company hopes to ha

Rubius launches $200m IPO to fund red blood cell therapies

NIH abandons convalescent plasma trial in mild COVID

Data sets up ulcerative colitis expansion for BMS’ MS drug Z...

IL-6 hypothesis looking shaky as Kevzara fails COVID-19 tria...

Kadmon preps filing for GVHD drug belumosudil after phase 3 ...

Innovating in inflammation and immunology

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

immunology

Editor's Picks